Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jul 19;8(7):1058.
doi: 10.3390/jcm8071058.

The Potential of Cannabidiol as a Treatment for Psychosis and Addiction: Who Benefits Most? A Systematic Review

Albert Batalla  1 , Hella Janssen  2 , Shiral S Gangadin  2   3 , Matthijs G Bossong  2
Affiliations
Review

The Potential of Cannabidiol as a Treatment for Psychosis and Addiction: Who Benefits Most? A Systematic Review

Albert Batalla et al. J Clin Med. .

Abstract

The endogenous cannabinoid (eCB) system plays an important role in the pathophysiology of both psychotic disorders and substance use disorders (SUDs). The non-psychoactive cannabinoid compound, cannabidiol (CBD) is a highly promising tool in the treatment of both disorders. Here we review human clinical studies that investigated the efficacy of CBD treatment for schizophrenia, substance use disorders, and their comorbidity. In particular, we examined possible profiles of patients who may benefit the most from CBD treatment. CBD, either as monotherapy or added to regular antipsychotic medication, improved symptoms in patients with schizophrenia, with particularly promising effects in the early stages of illness. A potential biomarker is the level of anandamide in blood. CBD and THC mixtures showed positive effects in reducing short-term withdrawal and craving in cannabis use disorders. Studies on schizophrenia and comorbid substance use are lacking. Future studies should focus on the effects of CBD on psychotic disorders in different stages of illness, together with the effects on comorbid substance use. These studies should use standardized measures to assess cannabis use. In addition, future efforts should be taken to study the relationship between the eCB system, GABA/glutamate, and the immune system to reveal the underlying neurobiology of the effects of CBD.

Keywords: CBD; addiction; cannabidiol; cannabis; psychosis; schizophrenia; substance use disorders.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Study inclusion process. CBD: Cannabidiol; THC: Δ9-Tetrahydrocannabinol.
See this image and copyright information in PMC

References

    1. Rössler W., Joachim Salize H., van Os J., Riecher-Rössler A. Size of burden of schizophrenia and psychotic disorders. Eur. Neuropsychopharmacol. 2005;15:399–409. doi: 10.1016/j.euroneuro.2005.04.009. - DOI - PubMed
    1. Buckley P.F., Miller B.J., Lehrer D.S., Castle D.J. Psychiatric Comorbidities and Schizophrenia. Schizophr. Bull. 2009;35:383–402. doi: 10.1093/schbul/sbn135. - DOI - PMC - PubMed
    1. Volkow N.D. Substance Use Disorders in Schizophrenia—Clinical Implications of Comorbidity. Schizophr. Bull. 2009;35:469–472. doi: 10.1093/schbul/sbp016. - DOI - PMC - PubMed
    1. Fioravanti M., Carlone O., Vitale B., Cinti M.E., Clare L. A Meta-Analysis of Cognitive Deficits in Adults with a Diagnosis of Schizophrenia. Neuropsychol. Rev. 2005;15:73–95. doi: 10.1007/s11065-005-6254-9. - DOI - PubMed
    1. Tandon R., Nasrallah H.A., Keshavan M.S. Schizophrenia, “just the facts” 4. Clinical features and conceptualization. Schizophr. Res. 2009;110:1–23. doi: 10.1016/j.schres.2009.03.005. - DOI - PubMed

LinkOut - more resources